Table 1. Demographic and clinical characteristics of study subjects.
| Unaffected comparison (UC) n=29 | Clinical high risk, not psychotic (CHR-NP) n=37 | Clinical high risk, psychotic (CHR-P) n=30 | |
|---|---|---|---|
| Age, average (s.d.) | 19.3 (4.4) | 18.1 (3.8) | 18.7 (3.7) |
| Ancestry | |||
| % Caucasian | 61%, | 65% | 52% |
| % African | 32% | 13.5% | 19% |
| % Asian | 7% | 13.5% | 19% |
| % Mixed | 0% | 8% | 10% |
| Sex, % male | 68% | 62% | 74% |
| SES, average (s.d.) | 7.5 (1.7) | 6.5 (1.7) | 6.2 (1.6) |
| Peripheral blood mononuclear cells | |||
| Neutrophils % | 56 (11) | 55 (13) | 55 (10) |
| Lymphocytes % | 34 (9) | 35 (11) | 33 (9) |
| Monocytes % | 8 (2) | 7 (3) | 8 (3) |
| Eosinophils % | 2 (3) | 2 (2) | 2 (2) |
| Basophils % | 1 (1) | 1 (1) | 1 (1) |
| SOPS scores, average (s.d.) | |||
| Totala | 4.8 (5.3) | 36.8 (12.4) | 45.0 (13.0) |
| Positivea | 1.3 (1.8) | 12.6 (4.4) | 13.9 (3.7) |
| Negativea | 1.3 (1.8) | 11.5 (5.9) | 14.0 (5.9) |
| Disorganizeda | .8 (1.1) | 4.9 (2.6) | 6.2 (3.4) |
| Generala,b | 1.4 (1.7) | 7.8 (4.5) | 10.9 (4.7) |
| Prescription medication | |||
| Antipsychoticc | 0% | 27% | 13% |
| Antidepressantd | 3% | 24% | 23% |
| Stimulant | 0% | 7% | 6% |
| Mood stabilizer | 0% | 0% | 3% |
| Benzodiazepinee | 0% | 3% | 13% |
| NSAID | 0% | 0% | 0% |
| Antibiotic | 0% | 0% | 0% |
| Substance use | |||
| Tobacco usef | 7% | 30% | 39% |
| Alcohol use | 41% | 38% | 35% |
| Marijuana useg | 7% | 24% | 32% |
Abbreviations: NSAID, non-steroidal anti-inflammatory drug; SES, socioeconomic status.
a
CHR-P vs UC t-test P-value<0.0001, CHR-NP vs UC t-test P-value<0.0001.
b
CHR-P vs CHR-NP t-test P-value=0.02.
c
CHR-P vs UC FET P-value=0.047, CHR-NP vs UC FET P-value=0.001.
d
CHR-P vs UC FET P-value=0.011, CHR-NP vs UC FET P-value=0.002.
e
CHR-P vs UC FET P-value=0.047.
f
CHR-P vs UC FET P-value=0.001, CHR-NP vs UC FET P-value=0.02.
g
CHR-P vs UC FET P-value=0.020, CHR-NP vs UC FET P-value=0.056.